Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Liked2Thinkon Apr 26, 2021 7:16pm
92 Views
Post# 33071788

RE:What was expected in the last CC fell flat.

RE:What was expected in the last CC fell flat.Them doing this current plan isnt what is bad.  In the end its the right way to go.  Would had been nice if they had decided to say this had to be this way at any point leading up to it but thats not Stage's way.

The problem is the timing now.  

LOI signed off end of June lets say.
Time table to get the new company together and integrate them into Stage's systems
When will that be done?  August?  September? who knows
All along that way we will continue to see problems reporting finacials.
Does this mean aristotle doesnt get rolling until towards the end of the year?
If so where is covid at that time?  Are we testing away like people think or will it dip down a good amount with so many people getting the vacinne in that period of time.

So this is why we get the sell off
1. Massive mistake with rollout
2. Realization that their revenue will drop considerably before they can get aristotle rolling if covid testing decreases
3. Why keep money in this company doing nothing for the next 4-6 months.  Maybe after that investors come back.

What is the only card Tripp can play that will turn it around?  Is Care Oncology using Aristotle today even though the LOI hasnt been signed?  I would assume they are but its not been said.  Even if they werent doing the LOI I assume they would still be using the test.  Is that where the uptick in cancer revenue came from?  If so why not say that??  Where they using the other products in the suite and are now using arisitotle?  If they did 500K in cancer in Q4 then maybe they will do 750-1M in Q1. Is that due to Care and because they have been working with them before that led to Stage wanting to buy them?

As always Stage = total guessing game and we will likely never have the facts.

probably 65 cents tomorrow.  Would be nice to see insider buying at least
<< Previous
Bullboard Posts
Next >>